Bayer AG said U.S. regulators approved its contrast agent for use in magnetic resonance imaging (MRI) to assess patients with known or suspected coronary artery disease. The injection, Gadavist, is an approved agent for use in MRI of the central nervous system and breasts. Gadavist is the only contrast agent approved by the FDA for use in cardiacMR, Bayer said.
Reuters
